## Novavax Faces Boardroom Revolt as Shah Capital Opposes Directors and Executive Pay
Activist investor Shah Capital is mounting a direct challenge to Novavax's leadership, announcing plans to vote against the re-election of board nominees and the company's executive compensation package at the upcoming annual meeting. The move signals renewed and intensifying pressure for operational changes at the vaccine maker, which has struggled to maintain its footing in a post-pandemic market. Shah Capital, which owns a 9% stake and is Novavax's second-largest shareholder, is leveraging its significant position to force a strategic shift, framing the vote as a referendum on current management's performance.

In a detailed letter to the company, hedge fund founder Himanshu Shah explicitly criticized management for failing to implement aggressive cost-cutting measures. The fund is now urging leadership to immediately reduce operational costs and to opportunistically buy back between 10 million and 20 million shares. This public confrontation highlights a fundamental disagreement over the company's financial stewardship and strategic direction, moving beyond private negotiations into a public campaign for influence.

The impending shareholder vote creates immediate uncertainty for Novavax's governance and could precipitate a broader restructuring if the activist campaign gains traction with other investors. The focus on cost discipline and capital allocation underscores the intense scrutiny facing biotech firms navigating a tighter funding environment. This boardroom battle places Novavax's leadership under direct fire, testing their ability to maintain control and execute their vision while a major investor demands a different path forward.
---
- **Source**: STAT News
- **Sector**: The Vault
- **Tags**: activist_investor, shareholder_revolt, corporate_governance, biotech, executive_compensation
- **Credibility**: unverified
- **Published**: 2026-04-08 13:57:01
- **ID**: 55173
- **URL**: https://whisperx.ai/en/intel/55173